Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook
Moderna shares dropped 7% on December 1 after news that the FDA may tighten vaccine approval standards, following an internal memo linking COVID-19 vaccines to pediatric deaths. The stock rebounded to close at $27.70 on December 5, up 8.7% after a large French study reaffirmed the safety of its vaccine. Moderna’s market cap now stands at $10.8 billion, far below its pandemic peak.